K-Clip, TriClip and LuX-Valve Plus: Heart Valve Options
Direct Answer
K-Clip, TriClip and LuX-Valve Plus are different transcatheter approaches to the tricuspid valve. Huihe describes K-Clip as an annuloplasty system that folds a portion of the supporting annulus to reduce its size. Abbott describes TriClip as leaflet edge-to-edge repair. Jenscare describes LuX-Valve Plus as a prosthetic valve replacement system. Implant count is not a measure of clinical superiority: whether a repair needs one implant or several depends on anatomy and the treating team’s plan. Country of development does not determine individual suitability.
Why Mechanism Matters More Than Device Count
Tricuspid regurgitation is a condition in which the valve does not close completely and blood leaks backward. The three systems above address that problem in fundamentally different ways. One reshapes part of the valve’s supporting ring, one brings leaflet edges together, and one removes the native valve from the functional path by implanting a replacement. These are not small technical variations. They represent different strategies, different device designs and different questions during evaluation.
A proposal involving several clips is not automatically worse than one involving a single implant. Ask what each implant is intended to achieve, which valve it targets, and what uncertainty remains. Different mechanisms cannot be ranked simply by counting implants. Comparative claims require appropriate clinical evidence.
Focal Annuloplasty: K-Clip
Huihe’s product page describes a Kay-inspired annuloplasty mechanism that folds part of the annulus to reduce its size. This localized repair is not a complete circumferential ring and does not replace the valve. The Shanghai regulator’s separate notice concerns approval of the transcatheter tricuspid annuloplasty system and its defined indication.
The approved indication described in the same regulator notice concerns isolated severe tricuspid regurgitation without need for concomitant left-sided valve surgery, and the notice includes further clinical restrictions. Those restrictions are part of the regulatory description, not a checklist that patients can use to decide whether they qualify. Reading a restriction and concluding “that sounds like me” is not the same as a clinical assessment. It is also inaccurate to describe one focal repair as fixing two valves, or to assume that one device is always sufficient. Those claims are not supported by the references cited here.
Leaflet Edge-to-Edge Repair: TriClip
Abbott describes TriClip as its transcatheter edge-to-edge repair system for the tricuspid valve. In this approach, the device approximates leaflet edges, which is a different mechanism from focal annuloplasty and different again from valve replacement. The distinction is worth stating plainly because the three terms are sometimes used loosely in conversation.
Two cautions follow from the manufacturer’s product information. First, no universal measurement cutoff should be assumed for eligibility. Figures that circulate online as fixed thresholds are not established by the reference cited here, and applying them as if they were universal would be misleading. Second, device count should not be read as a ranking. The existence of multiple transcatheter repair systems does not demonstrate that any one of them is superior. It is also important not to confuse TriClip with MitraClip, which is a different device intended for the mitral valve. Similar-sounding names refer to different anatomies and different clinical contexts.
Transcatheter Valve Replacement: LuX-Valve Plus
Jenscare describes LuX-Valve Plus as a transcatheter tricuspid valve replacement device delivered through a transvascular approach. It implants a prosthetic valve to take over valve function, rather than clipping the native leaflets. Ask the treating team which access site would be used and what the procedure would involve in your case.
Manufacturer design statements describe how a device is built and how it is intended to be used. They are not comparative clinical evidence, and they should not be treated as proof that one approach outperforms another. The product information cited here does not establish universal size eligibility, procedure duration, hospital stay or success rates, and none of those should be assumed or repeated as if they were settled facts.
Questions to Ask Before Seeking Assessment
The following are questions to raise with a qualified clinician or with a care coordination service. They are not clinical facts, and they are not a self-assessment tool.
- Which of these mechanisms — focal annuloplasty, leaflet edge-to-edge repair or valve replacement — is being considered for me, and why?
- What specific imaging and diagnostic information is needed before that question can be answered?
- Does my situation involve isolated tricuspid regurgitation, or are other valves also involved?
- What does the regulatory approval status of a given device mean for how it can be used in my case?
- What is known and what remains uncertain about the evidence for each option?
- What written confirmation can be provided about device availability, hospital arrangements and cost before any commitment?
- Who is responsible for the clinical decision, and what is the process for obtaining an individual assessment?
How China Medical Services Fits In
China Medical Services is a non-clinical care coordinator. It does not diagnose, recommend a device, determine eligibility or provide treatment. Its role is practical coordination: helping patients understand what information a hospital needs, how to request written confirmation of arrangements, and how to organize records for an individual medical assessment in China. Hospital arrangements and access require case-specific written confirmation, and no appointment, timeline or outcome should be assumed in advance.
If you would like help preparing questions and records for that kind of assessment, you can start here: https://chinamedservices.com/companion/. The main site is https://chinamedservices.com/.
FAQ
Is one of these three devices better than the others?
The references cited here do not establish superiority for any of them. They describe different mechanisms: focal annuloplasty, leaflet edge-to-edge repair and valve replacement. Comparative claims would require comparative clinical evidence, which is separate from product and regulatory descriptions.
Does a device being developed in China make it more suitable for me?
Country of development is not evidence of superiority and does not determine individual suitability. It may be relevant to regulatory context and local availability, but the clinical question is separate.
Can I use the approved indication for K-Clip to decide whether I qualify?
No. The regulator notice describes an approved indication with further clinical restrictions, but those are regulatory descriptions, not self-assessment criteria. Eligibility is an individual medical determination.
Is TriClip the same as MitraClip?
No. They are different devices. MitraClip is a mitral device, and the names should not be used interchangeably.
Does LuX-Valve Plus clip the leaflets?
No. It is a transcatheter tricuspid valve replacement device using transvascular access. It replaces the valve rather than clipping or approximating leaflets.
References
- Shanghai Medical Products Administration: Tricuspid valve repair system approval — https://yjj.sh.gov.cn/zjyw/20250311/0e7cb415716d494cb8a06f65546da7f2.html
- Abbott: TriClip transcatheter tricuspid valve repair — https://www.structuralheart.abbott/products/transcatheter-valve-repair/triclip
- Jenscare: LuX-Valve Plus product information — https://en.jenscare.com/product/180.html
- Huihe: KClip product and annuloplasty mechanism
General information for care planning, not a diagnosis or personal treatment recommendation. Clinical decisions belong to qualified treating professionals.
